NCT04982445 - Study Using CABENUVA™ for the Treatment of Human Immunodeficiency Virus (HIV)-1, Administered in Infusion Centers (IC) or Alternate Sites of Administration (ASA) in the United States (U.S.) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 18, 2021

Primary Completion Date

January 31, 2024

Study Completion Date

January 31, 2024

Conditions

HIV Infections

Interventions

DRUG

CABENUVA

CABENUVA will be administered IM at infusion centers/ASAs

Trial Locations (15)

GSK Investigational Site, Greensboro

GSK Investigational Site, Raleigh

GSK Investigational Site, Charlotte

GSK Investigational Site, West Columbia

GSK Investigational Site, Charleston

GSK Investigational Site, Summerville

GSK Investigational Site, Florence

GSK Investigational Site, Evans

GSK Investigational Site, East Lansing

GSK Investigational Site, Plymouth

GSK Investigational Site, Plano

GSK Investigational Site, Kingwood

GSK Investigational Site, Novi

GSK Investigational Site, Fort Worth

GSK Investigational Site, North Richland Hills